ABOUT THE PRODUCT
PCLX-001 is a first-in-class NMT1/NMT2 inhibitor currently in Phase 2 clinical trials for refractory colorectal cancer and acute myeloid leukemia (AML).
Information is owner-confirmed
Last updated 5 months ago
Price range
Other products/services from Greenfire Bio
GRN-300
Pharmaceutical
N/A
Greenfire Bio
United States (US)